One of the earliest hormone therapies (ADT) given to men to treat prostate cancer was estrogen. Estrogen, commonly known as the female hormone, was used as an ADT treatment in the early 1950s. […]
At some point in the progression of advanced prostate cancer the usual initial standard of care, hormone therapy (ADT2 or ADT3), will fail to control the progression of the cancer. Commonly, when ADT does fail we will experience an increase in our PSA scores and often see signs of disease progression on imaging tests. For [...]
For men with advanced prostate cancer adjuvant radiation therapy improves the cancer-specific survival of men with seminal vesicle invasion, even in the presence of nodal metastases. This underscores the need for multi-modal treatment approaches in advanced prostate cancer patients. Joel T. Nowak, M.A., M.S.W.
Ortho Biotech & Development, a unit of Cougar Biotechnology, Inc. has unblinded their Phase 3 study of abiraterone acetate plus prednisone. In the trial the abiraterone was used for the treatment of men with metastatic advanced prostate cancer has progressed following treatment with one or two chemotherapy regimens at least one of which contained docetaxel. [...]
The taxotere burn is not the hottest, latest dance sweeping the country, it is a little discussed complication that can strike a man while having chemotherapy for the treatment of prostate cancer. If the infusion equipment is not secured tightly or the vein not properly accessed and any of the taxotere is allowed to leak [...]